Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chad E Mire

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Viruses|November 27, 2024
Vesicular Stomatitis Virus Transmission Dynamics Within Its Endemic Range in Chiapas, MexicoLawrence H Zhou, Federico Valdez, Irene Lopez Gonzalez, et al.
Nature|April 23, 2015
Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primatesEmily P Thi, Chad E Mire, Amy C H Lee, et al.
Science Translational Medicine|June 27, 2014
Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibodyThomas W Geisbert, Chad E Mire, Joan B Geisbert, et al.
The Journal of Infectious Diseases|June 26, 2015
Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola VirusDemetrius Matassov, Andrea Marzi, Terri Latham, et al.
The Journal of Clinical Investigation|November 7, 2017
siRNA rescues nonhuman primates from advanced Marburg and Ravn virus diseaseEmily P Thi, Chad E Mire, Amy Ch Lee, et al.
Journal of Virology|December 18, 2015
Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR PathwaySowmya Pattabhi, Courtney R Wilkins, Ran Dong, et al.
Cell Reports|September 19, 2019
A VP35 Mutant Ebola Virus Lacks Virulence but Can Elicit Protective Immunity to Wild-Type Virus ChallengeCourtney Woolsey, Andrea R Menicucci, Robert W Cross, et al.
NPJ Vaccines|April 26, 2022
A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2Philipp A Ilinykh, Sivakumar Periasamy, Kai Huang, et al.
Antiviral Research|August 18, 2016
Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodiesRobert W Cross, Chad E Mire, Luis M Branco, et al.
Scientific Reports|February 22, 2020
Immune correlates of postexposure vaccine protection against Marburg virusCourtney Woolsey, Allen Jankeel, Demetrius Matassov, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Viruses|November 27, 2024
Vesicular Stomatitis Virus Transmission Dynamics Within Its Endemic Range in Chiapas, MexicoLawrence H Zhou, Federico Valdez, Irene Lopez Gonzalez, et al.
Nature|April 23, 2015
Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primatesEmily P Thi, Chad E Mire, Amy C H Lee, et al.
Science Translational Medicine|June 27, 2014
Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibodyThomas W Geisbert, Chad E Mire, Joan B Geisbert, et al.
The Journal of Infectious Diseases|June 26, 2015
Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola VirusDemetrius Matassov, Andrea Marzi, Terri Latham, et al.
The Journal of Clinical Investigation|November 7, 2017
siRNA rescues nonhuman primates from advanced Marburg and Ravn virus diseaseEmily P Thi, Chad E Mire, Amy Ch Lee, et al.
Journal of Virology|December 18, 2015
Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR PathwaySowmya Pattabhi, Courtney R Wilkins, Ran Dong, et al.
Cell Reports|September 19, 2019
A VP35 Mutant Ebola Virus Lacks Virulence but Can Elicit Protective Immunity to Wild-Type Virus ChallengeCourtney Woolsey, Andrea R Menicucci, Robert W Cross, et al.
NPJ Vaccines|April 26, 2022
A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2Philipp A Ilinykh, Sivakumar Periasamy, Kai Huang, et al.
Antiviral Research|August 18, 2016
Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodiesRobert W Cross, Chad E Mire, Luis M Branco, et al.
Scientific Reports|February 22, 2020
Immune correlates of postexposure vaccine protection against Marburg virusCourtney Woolsey, Allen Jankeel, Demetrius Matassov, et al.
Pageof 10